{"id":775732,"date":"2023-08-04T19:55:27","date_gmt":"2023-08-04T23:55:27","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/iterum-therapeutics-to-provide-business-update-and-report-second-quarter-2023-financial-results-on-august-11-2023\/"},"modified":"2023-08-04T19:55:27","modified_gmt":"2023-08-04T23:55:27","slug":"iterum-therapeutics-to-provide-business-update-and-report-second-quarter-2023-financial-results-on-august-11-2023","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/iterum-therapeutics-to-provide-business-update-and-report-second-quarter-2023-financial-results-on-august-11-2023\/","title":{"rendered":"Iterum Therapeutics to Provide Business Update and Report Second Quarter 2023 Financial Results on August 11, 2023"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">DUBLIN, Ireland and CHICAGO, Aug.  04, 2023  (GLOBE NEWSWIRE) &#8212; Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced that\u00a0the Company will release its second quarter 2023 financial results before the open of the\u00a0U.S.\u00a0financial markets on\u00a0Friday, August 11, 2023. Management will host a conference call at\u00a08:30 a.m. ET\u00a0that day to discuss the Company\u2019s financial results and provide an update on its business.<\/p>\n<p>To access the call please dial 833-470-1428 (domestic) or <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=R2omG8bD1jxlWhKLyLL5NYIZhH5GebVXEPCq_Ln2byIL0ugQD1ywKyvMh_Y4X8W297vPghw-uwOOIlEep-FMZoq-jJWwf793sTFmowyDTfeba8PIueUyKwSXcj_cWdbfWiFI8BzbbWQ6OmfDwdlP3x7LxAoby4eC2C-9-0Ywv0YIblv-m1Xi7MQ9cYbxSDdmjKse4PCjwL9JK5AYb0NPxyqVVNLVt4GRcJ9Nj9pHSBDA41LxlJLGGIqek6dMivR8qPmxnaKClMAYCFA1sZ59BSsXr1jHpDTY89rIIhbjJJBVBmghhYnGxT0cNMGbqIEmGRuFqRh5RhNppGf8vsjknSY8vMHREu6tUb1a516-7SeJ9FIAzjRadlrbe5vnVNv7hPP2hsq--7MrhkAHN6DAb8DfVUXnVKM5TC8KQ1Loztjf0HjJHfsewTROhJtTk3R4_ZY-H9RW4BP93fTZlYNitnif0jEX81jW8bwElf5mjSY=\" rel=\"nofollow noopener\" target=\"_blank\">Global Dial-In Numbers<\/a> and refer to Access Code 927170. To pre-register for this call, please go to the following link: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=ujt1o0CjBzfptnbdTekq27GtFy4DSEHVDH-_N78gDmGET5kGy5grMHz-CH51qfSpCcFZ76gPzNvc4Q28sXiIr8wqqQxE6z9znXEXTmh_X_bAUqhc3wKm3m40hvnNFlVNojdQX3D8kP0rFjpJw0b4hJuUPB_0_UCE3ILI4iANDSZCjizA3ekkYKpFq9BKpC7I_OYIf6c8hX_WhHTMIjHcmkWvVNsPtZ0E9JNULchaoAQ=\" rel=\"nofollow noopener\" target=\"_blank\">https:\/\/www.netroadshow.com\/events\/login?show=74ebce94&amp;confId=53773<\/a>. The audio webcast can be accessed under \u201cFinancials &amp; Filings\u201d in the Investors section of the Company\u2019s website at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=JBOdQEgnkTRJbICuAR0whMnPfVciuO7BWMn7RmZtOV7GTv3RbAPrip0k3PNSVf3jyXgAHSRgkqNZC62w9ndZjQ==\" rel=\"nofollow noopener\" target=\"_blank\">www.iterumtx.com<\/a> following the call.<\/p>\n<p align=\"justify\">\n        <strong>About Iterum Therapeutics plc<\/strong>\n      <\/p>\n<p>Iterum Therapeutics plc is a clinical-stage pharmaceutical company dedicated to developing differentiated anti-infectives aimed at combatting the global crisis of multi-drug resistant pathogens to significantly improve the lives of people affected by serious and life-threatening diseases around the world. Iterum is currently advancing its first compound, sulopenem, a novel penem anti-infective compound, in Phase 3 clinical development with an oral formulation. Sulopenem also has an IV formulation. Sulopenem has demonstrated potent in vitro activity against a wide variety of gram-negative, gram-positive and anaerobic bacteria resistant to other antibiotics. Iterum has received Qualified Infectious Disease Product (QIDP) and Fast Track designations for its oral and IV formulations of sulopenem in seven indications. For more information, please visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=0UlzGvsV3HGfT6ZgiU27EGvK3Yb_LGJcmn1mqNkH0csxNFx3D5Z_sREIj2hbzlFGpJ5y3P1f9yc6t3ca_ZICAxvh_X3dmkB0RhnqYbjpRdg=\" rel=\"nofollow noopener\" target=\"_blank\">http:\/\/www.iterumtx.com<\/a>.<\/p>\n<p align=\"justify\">\n        <strong>Investor Contact:<\/strong><br \/>\n        <br \/>Judy Matthews<br \/>Chief Financial Officer <br \/>312-778-6073<br \/><u><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=ugskiS6pISkD7DeUu-4Ehq6uUGGNRy3Wt3rOaNIus8bqfFVU2-eKFrdWdvDmqkVcCEz3CICRUOGr_rjmRQJBxA==\" rel=\"nofollow noopener\" target=\"_blank\">IR@iterumtx.com<\/a><\/u>\u00a0<\/p>\n<p \/>\n      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg4ODAwMiM1NzM4OTcwIzIyMDkwNTQ=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/MWIyZDYwNDgtMDA4OS00MDk1LTk3NDUtZjM5YTE4M2Y2YzE4LTEyMjA2MDc=\/tiny\/Iterum-Therapeutics-PLC.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>DUBLIN, Ireland and CHICAGO, Aug. 04, 2023 (GLOBE NEWSWIRE) &#8212; Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced that\u00a0the Company will release its second quarter 2023 financial results before the open of the\u00a0U.S.\u00a0financial markets on\u00a0Friday, August 11, 2023. Management will host a conference call at\u00a08:30 a.m. ET\u00a0that day to discuss the Company\u2019s financial results and provide an update on its business. To access the call please dial 833-470-1428 (domestic) or Global Dial-In Numbers and refer to Access Code 927170. To pre-register for this call, please go to the following link: https:\/\/www.netroadshow.com\/events\/login?show=74ebce94&amp;confId=53773. The &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/iterum-therapeutics-to-provide-business-update-and-report-second-quarter-2023-financial-results-on-august-11-2023\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Iterum Therapeutics to Provide Business Update and Report Second Quarter 2023 Financial Results on August 11, 2023&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-775732","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Iterum Therapeutics to Provide Business Update and Report Second Quarter 2023 Financial Results on August 11, 2023 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/iterum-therapeutics-to-provide-business-update-and-report-second-quarter-2023-financial-results-on-august-11-2023\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Iterum Therapeutics to Provide Business Update and Report Second Quarter 2023 Financial Results on August 11, 2023 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"DUBLIN, Ireland and CHICAGO, Aug. 04, 2023 (GLOBE NEWSWIRE) &#8212; Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced that\u00a0the Company will release its second quarter 2023 financial results before the open of the\u00a0U.S.\u00a0financial markets on\u00a0Friday, August 11, 2023. Management will host a conference call at\u00a08:30 a.m. ET\u00a0that day to discuss the Company\u2019s financial results and provide an update on its business. To access the call please dial 833-470-1428 (domestic) or Global Dial-In Numbers and refer to Access Code 927170. To pre-register for this call, please go to the following link: https:\/\/www.netroadshow.com\/events\/login?show=74ebce94&amp;confId=53773. The &hellip; Continue reading &quot;Iterum Therapeutics to Provide Business Update and Report Second Quarter 2023 Financial Results on August 11, 2023&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/iterum-therapeutics-to-provide-business-update-and-report-second-quarter-2023-financial-results-on-august-11-2023\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-08-04T23:55:27+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg4ODAwMiM1NzM4OTcwIzIyMDkwNTQ=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/iterum-therapeutics-to-provide-business-update-and-report-second-quarter-2023-financial-results-on-august-11-2023\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/iterum-therapeutics-to-provide-business-update-and-report-second-quarter-2023-financial-results-on-august-11-2023\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Iterum Therapeutics to Provide Business Update and Report Second Quarter 2023 Financial Results on August 11, 2023\",\"datePublished\":\"2023-08-04T23:55:27+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/iterum-therapeutics-to-provide-business-update-and-report-second-quarter-2023-financial-results-on-august-11-2023\\\/\"},\"wordCount\":305,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/iterum-therapeutics-to-provide-business-update-and-report-second-quarter-2023-financial-results-on-august-11-2023\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODg4ODAwMiM1NzM4OTcwIzIyMDkwNTQ=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/iterum-therapeutics-to-provide-business-update-and-report-second-quarter-2023-financial-results-on-august-11-2023\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/iterum-therapeutics-to-provide-business-update-and-report-second-quarter-2023-financial-results-on-august-11-2023\\\/\",\"name\":\"Iterum Therapeutics to Provide Business Update and Report Second Quarter 2023 Financial Results on August 11, 2023 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/iterum-therapeutics-to-provide-business-update-and-report-second-quarter-2023-financial-results-on-august-11-2023\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/iterum-therapeutics-to-provide-business-update-and-report-second-quarter-2023-financial-results-on-august-11-2023\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODg4ODAwMiM1NzM4OTcwIzIyMDkwNTQ=\",\"datePublished\":\"2023-08-04T23:55:27+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/iterum-therapeutics-to-provide-business-update-and-report-second-quarter-2023-financial-results-on-august-11-2023\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/iterum-therapeutics-to-provide-business-update-and-report-second-quarter-2023-financial-results-on-august-11-2023\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/iterum-therapeutics-to-provide-business-update-and-report-second-quarter-2023-financial-results-on-august-11-2023\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODg4ODAwMiM1NzM4OTcwIzIyMDkwNTQ=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODg4ODAwMiM1NzM4OTcwIzIyMDkwNTQ=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/iterum-therapeutics-to-provide-business-update-and-report-second-quarter-2023-financial-results-on-august-11-2023\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Iterum Therapeutics to Provide Business Update and Report Second Quarter 2023 Financial Results on August 11, 2023\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Iterum Therapeutics to Provide Business Update and Report Second Quarter 2023 Financial Results on August 11, 2023 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/iterum-therapeutics-to-provide-business-update-and-report-second-quarter-2023-financial-results-on-august-11-2023\/","og_locale":"en_US","og_type":"article","og_title":"Iterum Therapeutics to Provide Business Update and Report Second Quarter 2023 Financial Results on August 11, 2023 - Market Newsdesk","og_description":"DUBLIN, Ireland and CHICAGO, Aug. 04, 2023 (GLOBE NEWSWIRE) &#8212; Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced that\u00a0the Company will release its second quarter 2023 financial results before the open of the\u00a0U.S.\u00a0financial markets on\u00a0Friday, August 11, 2023. Management will host a conference call at\u00a08:30 a.m. ET\u00a0that day to discuss the Company\u2019s financial results and provide an update on its business. To access the call please dial 833-470-1428 (domestic) or Global Dial-In Numbers and refer to Access Code 927170. To pre-register for this call, please go to the following link: https:\/\/www.netroadshow.com\/events\/login?show=74ebce94&amp;confId=53773. The &hellip; Continue reading \"Iterum Therapeutics to Provide Business Update and Report Second Quarter 2023 Financial Results on August 11, 2023\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/iterum-therapeutics-to-provide-business-update-and-report-second-quarter-2023-financial-results-on-august-11-2023\/","og_site_name":"Market Newsdesk","article_published_time":"2023-08-04T23:55:27+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg4ODAwMiM1NzM4OTcwIzIyMDkwNTQ=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/iterum-therapeutics-to-provide-business-update-and-report-second-quarter-2023-financial-results-on-august-11-2023\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/iterum-therapeutics-to-provide-business-update-and-report-second-quarter-2023-financial-results-on-august-11-2023\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Iterum Therapeutics to Provide Business Update and Report Second Quarter 2023 Financial Results on August 11, 2023","datePublished":"2023-08-04T23:55:27+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/iterum-therapeutics-to-provide-business-update-and-report-second-quarter-2023-financial-results-on-august-11-2023\/"},"wordCount":305,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/iterum-therapeutics-to-provide-business-update-and-report-second-quarter-2023-financial-results-on-august-11-2023\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg4ODAwMiM1NzM4OTcwIzIyMDkwNTQ=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/iterum-therapeutics-to-provide-business-update-and-report-second-quarter-2023-financial-results-on-august-11-2023\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/iterum-therapeutics-to-provide-business-update-and-report-second-quarter-2023-financial-results-on-august-11-2023\/","name":"Iterum Therapeutics to Provide Business Update and Report Second Quarter 2023 Financial Results on August 11, 2023 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/iterum-therapeutics-to-provide-business-update-and-report-second-quarter-2023-financial-results-on-august-11-2023\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/iterum-therapeutics-to-provide-business-update-and-report-second-quarter-2023-financial-results-on-august-11-2023\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg4ODAwMiM1NzM4OTcwIzIyMDkwNTQ=","datePublished":"2023-08-04T23:55:27+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/iterum-therapeutics-to-provide-business-update-and-report-second-quarter-2023-financial-results-on-august-11-2023\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/iterum-therapeutics-to-provide-business-update-and-report-second-quarter-2023-financial-results-on-august-11-2023\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/iterum-therapeutics-to-provide-business-update-and-report-second-quarter-2023-financial-results-on-august-11-2023\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg4ODAwMiM1NzM4OTcwIzIyMDkwNTQ=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg4ODAwMiM1NzM4OTcwIzIyMDkwNTQ="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/iterum-therapeutics-to-provide-business-update-and-report-second-quarter-2023-financial-results-on-august-11-2023\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Iterum Therapeutics to Provide Business Update and Report Second Quarter 2023 Financial Results on August 11, 2023"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/775732","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=775732"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/775732\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=775732"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=775732"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=775732"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}